

PRESS RELEASE



Hansa Biopharma Nomination Committee formed

Lund November 2, 2020. Hansa Biopharma today announced that the Nomination Committee has been formed in accordance with the principles adopted by the Annual General Meeting (AGM) on June 23, 2020 and has the following composition:

- Natalie Berner representing Redmile Group
- Thomas Olausson
- Jannis Kitsakis representing AP4
- Ulf Wiinberg, Chairman of the Board

The Chairman of the Board shall also summon the first meeting of the Nomination Committee.

The function of the Nomination Committee is to prepare and submit proposals for the AGM regarding the number of board members to be elected by the general meeting, election of chairman and other board members, board fees and any remuneration for committee work, election of the chairman of the AGM, election of auditors (if applicable) and fee for the auditors, and proposals for rules for appointing the Nomination Committee.

The proposals of the Nomination Committee will be presented in the notice of the Annual General Meeting 2021 and will be published on Hansa Biopharma's website.

Shareholders wishing to submit comments or proposals to the Nomination Committee may do so via e-mail to ir@hansabiopharma.com or by letter to Hansa Biopharma, Nomination Committee, Box 785, 220 07 Lund, Sweden.

This is information that Hansa Biopharma AB is obliged to make public pursuant to the EU Market Abuse Regulation.

This is information that Hansa Biopharma AB is obliged to make public pursuant to the EU Market Abuse Regulation.

The information was submitted for publication, through the contact person set out below, at 8:00 a.m. (CET) on November 2, 2020.

Contact information

Klaus Sindahl
Head of Investor Relations
Hansa Biopharma
M: +46 (0) 709-298 269
E: klaus.sindahl@hansabiopharma.com

Katja Margell
Head of Corporate Communications
Hansa Biopharma
M: +46 (0) 768-198 326
E: katja.margell@hansabiopharma.com

About Hansa Biopharma

Hansa Biopharma is leveraging its proprietary enzyme technology platform to develop immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy and cancer.

The Company's lead product candidate, imlifidase, is an antibody cleaving enzyme being developed to enable kidney transplantation in highly sensitized patients and may be further developed for use in other organ and tissue transplantation as well as acute autoimmune indications.

Imlifidase has been granted conditional approval in the European Union for the desensitization treatment of highly sensitized adult kidney transplant patients with a positive crossmatch against an available deceased donor. Commercial launch in select European countries is expected in the fourth quarter of 2020.

Hansa's research and development program is advancing the Company's enzyme technology to develop the next generation of IgG-cleaving enzymes with potentially lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases, gene therapy and oncology. Hansa Biopharma is based in Lund, Sweden and has operations in both Europe and the U.S.

Hansa Biopharma
Scheelevägen 22
SE- 223 63 Lund, Sweden
Phone: +46 46 16 56 70
www.hansabiopharma.com

Nasdaq OMX Stockholm